23.92

7.29% -1.88

After Hours: 23.995 0.075 +0.31%

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is currently priced at $23.92, with a 24-hour trading volume of 120.52K. It has seen a -7.29% decreased in the last 24 hours and a -4.66% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $25.33 pivot point. If it approaches the $22.18 support level, significant changes may occur.

Previous Close:

$25.80

Open:

$25.8

24h Volume:

120.52K

Market Cap:

$702.02M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+9.22%

1M Performance:

-4.66%

6M Performance:

+104.79%

1Y Performance:

+0.00%

1D Range:

$23.79

$27.63

52W Range:

$6.58

$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1215)

Industry

Biotechnology (700)

Phone

929-999-4055

Address

7 Times Square, 43rd Floor, New York

Employee

Twitter

Next Earnings Date

2024-05-23

Latest SEC Filings

DNTH's Discussions on Twitter

Dianthus Therapeutics Inc Stock (DNTH) Latest News

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics

Benzinga

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

GlobeNewswire Inc.

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation

Zacks Investment Research

Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks

Zacks Investment Research

Dianthus Therapeutics Inc Stock (DNTH) Financials Data

There is no financial data for Dianthus Therapeutics Inc (DNTH). Check out other stocks for more information.

Dianthus Therapeutics Inc Stock (DNTH) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Fairmount Funds Management LLC	Director	Sep 29 '23	Buy	13.63	24,670	336,252	1,928,503
Fairmount Funds Management LLC	Director	Sep 26 '23	Buy	13.15	30,000	394,500	1,903,833
Randhawa Simrat	Chief Medical Officer	Sep 22 '23	Buy	13.20	2,000	26,400	4,000
Randhawa Simrat	Chief Medical Officer	Sep 21 '23	Buy	13.20	2,000	26,400	2,000
Fairmount Funds Management LLC	Director	Sep 19 '23	Buy	13.20	30,000	396,000	1,873,833
Fairmount Funds Management LLC	Director	Sep 13 '23	Buy	11.76	9,367	110,156	1,843,833
Fairmount Funds Management LLC	Director	Sep 12 '23	Buy	10.85	14,887	161,524	1,834,466

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. is based in New York, New York.